Login to My NLA Account

Introduction

Article By:

Beth Sherry, MD

Preventive Cardiology Fellow
NYU Center for the Prevention of Cardiovascular Disease
New York, NY

Michael Garshick, MD

Assistant Professor of Medicine
NYU Center for the Prevention of Cardiovascular Disease
Director, Cardio-Rheumatology Program
New York, NY

0
No votes yet

Introduction

Article By:

Shubham Agarwal, MD

University of Texas Southwestern
Dallas, TX

Michael Madueke

Tulane University School of Medicine
New Orleans, LA

 

Keith C. Ferdinand, MD, FNLA*

Tulane University School of Medicine
New Orleans, LA

Juliana Savic, MD

Mayo Clinic Arizona
Scottsdale, AZ

Wenjun Fan, MD, PhD

University of California, Irvine
Irvine, CA

Zahid Ahmad, MD, FNLA*

NLA Diversity, Equity, Inclusion Committee Co-Chair
University of Texas Southwestern
Dallas, TX

0
No votes yet

Lipid Management in Specific Populations, the theme for this edition of LipidSpin, is a culmination of what Dr. Chima Nwizu, SWLA President, and I believe moves our organization forward. The National Lipid Association realizes the importance of understanding, investigating, and advocating treatment options for a variety of conditions; including those that afflict a limited population.

Article By:

Geeta Sikand, MA, RDN, FAND, CLS, FNLA*

President, Pacific Lipid Association
Irvine, CA

0
No votes yet

I am honored as the Southwest Lipid Association President, in collaboration with the President of the Pacific Lipid Association, to bring you the first LipidSpin edition of 2024.

Article By:

Chima Nwizu, MD, FAAFP, FNLA*

President, Southwest Lipid Association
Greeley, CO

0
No votes yet

As always, LipidSpin is a labor of love – to collaborate on a selection of contributions that we, as Lipid Specialists within the NLA, see as critically important topics for in depth review and dissemination.

Article By:

Kaye-Eileen Willard, MD, FNLA*

LipidSpin Co-Editor, National Lipid Association
Racine, WI

 

0
No votes yet

Hello fellow lipid lovers!

I hope everyone had a wonderful holiday season and is looking forward to a productive and prosperous 2024. The new year brings many exciting new initiatives and projects over the coming months, including but not limited to:

Article By:

Daniel E. Soffer, MD, FNLA*

President, National Lipid Association 
Philadelphia, PA

0
No votes yet

Clinical Case

Article By:

Naz Baecher, MD

University of Rochester
Department of Public Health Sciences
Rochester, NY

Robert Block, MD, FNLA

University of Rochester
Department of Public Health Sciences, 
Cardiology Division
Department of Medicine
Center for Community Health and Prevention
Rochester, NY

Greg Pokrywka, MD, FACP, FASPC, NCMP, FNLA

Director Baltimore Lipid Center
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

0
No votes yet
Last Updated: Friday, 29-Sep-2023 16:00:00 EDT

 

  • Olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels versus placebo
  • First study to show an absolute reduction in acute pancreatitis in FCS patients, with olezarsen 80 mg monthly dose reducing events by 100 percent 
  • Olezarsen demonstrated a favorable safety and tolerability profile
  • Ionis plans to file a New Drug Application with U.S. FDA in preparation for first potential independent launch

Introduction/Magnitude of The Problem

Article By:

Jared Segal, DO

Tower Health 

West Reading, PA

Prem Raj Parajuli, MD

Tower Health

West Reading, PA

Dharmesh Patel, MD, MBBS (Lon), FACC, FACP, FNLA, FASPC, RVPI

Stern Cardiovascular Foundation 

Memphis, Tennessee 

Aniruddha Singh, MD, FACC

Tower Health

West Reading, PA

0
No votes yet